Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression

An examination of children of depressed mothers at age 3–6 found that IQs are lower in these children than in children of nondepressed mothers, and behavioral problems are somewhat more common. However, neither difference was related to prenatal antidepressant dose or duration. The child’s IQ is inf...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of psychiatry 2012-11, Vol.169 (11), p.1165-1174
Hauptverfasser: Nulman, Irena, Koren, Gideon, Rovet, Joanne, Barrera, Maru, Pulver, Ariel, Streiner, David, Feldman, Brian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1174
container_issue 11
container_start_page 1165
container_title The American journal of psychiatry
container_volume 169
creator Nulman, Irena
Koren, Gideon
Rovet, Joanne
Barrera, Maru
Pulver, Ariel
Streiner, David
Feldman, Brian
description An examination of children of depressed mothers at age 3–6 found that IQs are lower in these children than in children of nondepressed mothers, and behavioral problems are somewhat more common. However, neither difference was related to prenatal antidepressant dose or duration. The child’s IQ is influenced by the mother’s IQ and child’s sex. Behavioral problems are associated with the severity of the mother’s depression not only during gestation but also during early childhood. ObjectiveEffects on child neurodevelopment of neurotransmitter reuptake inhibitors used as antidepressants during pregnancy have not been adequately studied. The authors compared the effects of prenatal exposure to venlafaxine (serotonin-norepinephrine reuptake inhibitor), selective serotonin reuptake inhibitors (SSRIs), and maternal depression.MethodA cohort derived from a prospectively collected database included four groups of children born to 1) depressed women who took venlafaxine during pregnancy (N=62), 2) depressed women who took SSRIs during pregnancy (N=62), 3) depressed women who were untreated during pregnancy (N=54), and 4) nondepressed, healthy women (N=62). The children’s intelligence and behavior outcomes were evaluated with standardized instruments at one time point between the ages of 3 years and 6 years, 11 months.ResultsThe children exposed to venlafaxine, SSRIs, and maternal depression during pregnancy had similar full-scale IQs (105, 105, and 108, respectively). The IQs of the venlafaxine and SSRI groups were significantly lower than that of the children of nondepressed mothers (112). The three groups exposed to maternal depression had consistently, but nonsignificantly, higher rates of most problematic behaviors than the children of nondepressed mothers. Severity of maternal depression in pregnancy and at testing predicted child behavior. Maternal IQ and child sex predicted child IQ. Antidepressant dose and duration during pregnancy did not predict any cognitive or behavioral outcome.ConclusionsFactors other than antidepressant exposure during pregnancy strongly predict children’s intellect and behavior. Depression during pregnancy is a significant risk factor for postpartum depression. Children of depressed mothers may be at risk of future psychopathology.
doi_str_mv 10.1176/appi.ajp.2012.11111721
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1466093672</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2914564481</sourcerecordid><originalsourceid>FETCH-LOGICAL-a446t-cdf5e15c9eb61162e447d515569882c4f4a9254e01d99f2dba6ad8c1601d09623</originalsourceid><addsrcrecordid>eNqNkdFuFCEUhonR2G31FRoSY9KLzhYYYIZLs7bapFaj1ng3YWfOWFYWEJhaX8MnlnW3NvHCyAWcc_Kd_wA_QoeUzClt5IkOwcz1KswZoayUymoYfYBmVNSiahhrH6IZIYRVStSf99B-SquSkrphj9EeqylrFatn6OclTNEPcAPWhzW4jP2IF9fGDhEcPvPW-u_GfcHvSqqztvj0Nvg0RcDZ40_grB71rXFwjD-AhT6bGyhR9Nk74_B7mELWXwGfu2uzNNnHdIx9xFcuR9AZBvym7NEV3ZcQIqRkvHuCHo3aJni6Ow_Q1dnpx8Xr6uLtq_PFi4tKcy5z1Q-jACp6BUtJqWTAeTMIKoRUbct6PnKtmOBA6KDUyIallnpoeypLgSjJ6gN0tNUN0X-bIOVubVIP1moHfkod5VISVcvmP1DKqWBKEl7QZ3-hKz9tXliougxXXJK2UHJL9dGnFGHsQjRrHX90lHQbg7uNwV0xuNsY3N0ZXBoPd_LTcg3Dn7Y7RwvwfAfo1Gs7Ru16k-45Wf5HUFW4esv9HnR_x3-P_wWDScH7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1316094608</pqid></control><display><type>article</type><title>Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression</title><source>MEDLINE</source><source>American Psychiatric Publishing</source><source>EZB Electronic Journals Library</source><creator>Nulman, Irena ; Koren, Gideon ; Rovet, Joanne ; Barrera, Maru ; Pulver, Ariel ; Streiner, David ; Feldman, Brian</creator><creatorcontrib>Nulman, Irena ; Koren, Gideon ; Rovet, Joanne ; Barrera, Maru ; Pulver, Ariel ; Streiner, David ; Feldman, Brian</creatorcontrib><description>An examination of children of depressed mothers at age 3–6 found that IQs are lower in these children than in children of nondepressed mothers, and behavioral problems are somewhat more common. However, neither difference was related to prenatal antidepressant dose or duration. The child’s IQ is influenced by the mother’s IQ and child’s sex. Behavioral problems are associated with the severity of the mother’s depression not only during gestation but also during early childhood. ObjectiveEffects on child neurodevelopment of neurotransmitter reuptake inhibitors used as antidepressants during pregnancy have not been adequately studied. The authors compared the effects of prenatal exposure to venlafaxine (serotonin-norepinephrine reuptake inhibitor), selective serotonin reuptake inhibitors (SSRIs), and maternal depression.MethodA cohort derived from a prospectively collected database included four groups of children born to 1) depressed women who took venlafaxine during pregnancy (N=62), 2) depressed women who took SSRIs during pregnancy (N=62), 3) depressed women who were untreated during pregnancy (N=54), and 4) nondepressed, healthy women (N=62). The children’s intelligence and behavior outcomes were evaluated with standardized instruments at one time point between the ages of 3 years and 6 years, 11 months.ResultsThe children exposed to venlafaxine, SSRIs, and maternal depression during pregnancy had similar full-scale IQs (105, 105, and 108, respectively). The IQs of the venlafaxine and SSRI groups were significantly lower than that of the children of nondepressed mothers (112). The three groups exposed to maternal depression had consistently, but nonsignificantly, higher rates of most problematic behaviors than the children of nondepressed mothers. Severity of maternal depression in pregnancy and at testing predicted child behavior. Maternal IQ and child sex predicted child IQ. Antidepressant dose and duration during pregnancy did not predict any cognitive or behavioral outcome.ConclusionsFactors other than antidepressant exposure during pregnancy strongly predict children’s intellect and behavior. Depression during pregnancy is a significant risk factor for postpartum depression. Children of depressed mothers may be at risk of future psychopathology.</description><identifier>ISSN: 0002-953X</identifier><identifier>EISSN: 1535-7228</identifier><identifier>DOI: 10.1176/appi.ajp.2012.11111721</identifier><identifier>PMID: 23128923</identifier><identifier>CODEN: AJPSAO</identifier><language>eng</language><publisher>Arlington, VA: American Psychiatric Association</publisher><subject>Abnormalities, Drug-Induced - diagnosis ; Abnormalities, Drug-Induced - physiopathology ; Adult ; Adult and adolescent clinical studies ; Antidepressants ; Antidepressive Agents, Second-Generation - adverse effects ; Antidepressive Agents, Second-Generation - therapeutic use ; Biological and medical sciences ; Case-Control Studies ; Child Behavior Disorders - chemically induced ; Child Behavior Disorders - physiopathology ; Child, Preschool ; Cyclohexanols - adverse effects ; Cyclohexanols - therapeutic use ; Depression ; Depressive Disorder - drug therapy ; Depressive Disorder - physiopathology ; Dose-Response Relationship, Drug ; Female ; Humans ; Infant ; Infant, Newborn ; Intelligence ; Intelligence - drug effects ; Intelligence - physiology ; Longitudinal Studies ; Male ; Medical sciences ; Mental depression ; Mood disorders ; Neonatal Abstinence Syndrome - diagnosis ; Neonatal Abstinence Syndrome - physiopathology ; Neuropharmacology ; Neuropsychology ; Pharmacology. Drug treatments ; Pregnancy ; Pregnancy Complications - drug therapy ; Pregnancy Complications - physiopathology ; Prenatal development ; Prenatal exposure ; Prenatal Exposure Delayed Effects ; Prospective Studies ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Reference Values ; Retrospective Studies ; Serotonin Uptake Inhibitors - adverse effects ; Serotonin Uptake Inhibitors - therapeutic use ; Sex Factors ; Venlafaxine Hydrochloride ; Wechsler Scales</subject><ispartof>The American journal of psychiatry, 2012-11, Vol.169 (11), p.1165-1174</ispartof><rights>Copyright © 2012 by the American Psychiatric Association 2012</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 by the American Psychiatric Association</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a446t-cdf5e15c9eb61162e447d515569882c4f4a9254e01d99f2dba6ad8c1601d09623</citedby><cites>FETCH-LOGICAL-a446t-cdf5e15c9eb61162e447d515569882c4f4a9254e01d99f2dba6ad8c1601d09623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ajp.2012.11111721$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ajp.2012.11111721$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>314,776,780,2842,21607,21608,21609,27903,27904,77540,77545</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=26569519$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23128923$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nulman, Irena</creatorcontrib><creatorcontrib>Koren, Gideon</creatorcontrib><creatorcontrib>Rovet, Joanne</creatorcontrib><creatorcontrib>Barrera, Maru</creatorcontrib><creatorcontrib>Pulver, Ariel</creatorcontrib><creatorcontrib>Streiner, David</creatorcontrib><creatorcontrib>Feldman, Brian</creatorcontrib><title>Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression</title><title>The American journal of psychiatry</title><addtitle>Am J Psychiatry</addtitle><description>An examination of children of depressed mothers at age 3–6 found that IQs are lower in these children than in children of nondepressed mothers, and behavioral problems are somewhat more common. However, neither difference was related to prenatal antidepressant dose or duration. The child’s IQ is influenced by the mother’s IQ and child’s sex. Behavioral problems are associated with the severity of the mother’s depression not only during gestation but also during early childhood. ObjectiveEffects on child neurodevelopment of neurotransmitter reuptake inhibitors used as antidepressants during pregnancy have not been adequately studied. The authors compared the effects of prenatal exposure to venlafaxine (serotonin-norepinephrine reuptake inhibitor), selective serotonin reuptake inhibitors (SSRIs), and maternal depression.MethodA cohort derived from a prospectively collected database included four groups of children born to 1) depressed women who took venlafaxine during pregnancy (N=62), 2) depressed women who took SSRIs during pregnancy (N=62), 3) depressed women who were untreated during pregnancy (N=54), and 4) nondepressed, healthy women (N=62). The children’s intelligence and behavior outcomes were evaluated with standardized instruments at one time point between the ages of 3 years and 6 years, 11 months.ResultsThe children exposed to venlafaxine, SSRIs, and maternal depression during pregnancy had similar full-scale IQs (105, 105, and 108, respectively). The IQs of the venlafaxine and SSRI groups were significantly lower than that of the children of nondepressed mothers (112). The three groups exposed to maternal depression had consistently, but nonsignificantly, higher rates of most problematic behaviors than the children of nondepressed mothers. Severity of maternal depression in pregnancy and at testing predicted child behavior. Maternal IQ and child sex predicted child IQ. Antidepressant dose and duration during pregnancy did not predict any cognitive or behavioral outcome.ConclusionsFactors other than antidepressant exposure during pregnancy strongly predict children’s intellect and behavior. Depression during pregnancy is a significant risk factor for postpartum depression. Children of depressed mothers may be at risk of future psychopathology.</description><subject>Abnormalities, Drug-Induced - diagnosis</subject><subject>Abnormalities, Drug-Induced - physiopathology</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antidepressants</subject><subject>Antidepressive Agents, Second-Generation - adverse effects</subject><subject>Antidepressive Agents, Second-Generation - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Case-Control Studies</subject><subject>Child Behavior Disorders - chemically induced</subject><subject>Child Behavior Disorders - physiopathology</subject><subject>Child, Preschool</subject><subject>Cyclohexanols - adverse effects</subject><subject>Cyclohexanols - therapeutic use</subject><subject>Depression</subject><subject>Depressive Disorder - drug therapy</subject><subject>Depressive Disorder - physiopathology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Intelligence</subject><subject>Intelligence - drug effects</subject><subject>Intelligence - physiology</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental depression</subject><subject>Mood disorders</subject><subject>Neonatal Abstinence Syndrome - diagnosis</subject><subject>Neonatal Abstinence Syndrome - physiopathology</subject><subject>Neuropharmacology</subject><subject>Neuropsychology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pregnancy</subject><subject>Pregnancy Complications - drug therapy</subject><subject>Pregnancy Complications - physiopathology</subject><subject>Prenatal development</subject><subject>Prenatal exposure</subject><subject>Prenatal Exposure Delayed Effects</subject><subject>Prospective Studies</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Reference Values</subject><subject>Retrospective Studies</subject><subject>Serotonin Uptake Inhibitors - adverse effects</subject><subject>Serotonin Uptake Inhibitors - therapeutic use</subject><subject>Sex Factors</subject><subject>Venlafaxine Hydrochloride</subject><subject>Wechsler Scales</subject><issn>0002-953X</issn><issn>1535-7228</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkdFuFCEUhonR2G31FRoSY9KLzhYYYIZLs7bapFaj1ng3YWfOWFYWEJhaX8MnlnW3NvHCyAWcc_Kd_wA_QoeUzClt5IkOwcz1KswZoayUymoYfYBmVNSiahhrH6IZIYRVStSf99B-SquSkrphj9EeqylrFatn6OclTNEPcAPWhzW4jP2IF9fGDhEcPvPW-u_GfcHvSqqztvj0Nvg0RcDZ40_grB71rXFwjD-AhT6bGyhR9Nk74_B7mELWXwGfu2uzNNnHdIx9xFcuR9AZBvym7NEV3ZcQIqRkvHuCHo3aJni6Ow_Q1dnpx8Xr6uLtq_PFi4tKcy5z1Q-jACp6BUtJqWTAeTMIKoRUbct6PnKtmOBA6KDUyIallnpoeypLgSjJ6gN0tNUN0X-bIOVubVIP1moHfkod5VISVcvmP1DKqWBKEl7QZ3-hKz9tXliougxXXJK2UHJL9dGnFGHsQjRrHX90lHQbg7uNwV0xuNsY3N0ZXBoPd_LTcg3Dn7Y7RwvwfAfo1Gs7Ru16k-45Wf5HUFW4esv9HnR_x3-P_wWDScH7</recordid><startdate>20121101</startdate><enddate>20121101</enddate><creator>Nulman, Irena</creator><creator>Koren, Gideon</creator><creator>Rovet, Joanne</creator><creator>Barrera, Maru</creator><creator>Pulver, Ariel</creator><creator>Streiner, David</creator><creator>Feldman, Brian</creator><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>ASE</scope><scope>FPQ</scope><scope>K6X</scope></search><sort><creationdate>20121101</creationdate><title>Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression</title><author>Nulman, Irena ; Koren, Gideon ; Rovet, Joanne ; Barrera, Maru ; Pulver, Ariel ; Streiner, David ; Feldman, Brian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a446t-cdf5e15c9eb61162e447d515569882c4f4a9254e01d99f2dba6ad8c1601d09623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Abnormalities, Drug-Induced - diagnosis</topic><topic>Abnormalities, Drug-Induced - physiopathology</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antidepressants</topic><topic>Antidepressive Agents, Second-Generation - adverse effects</topic><topic>Antidepressive Agents, Second-Generation - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Case-Control Studies</topic><topic>Child Behavior Disorders - chemically induced</topic><topic>Child Behavior Disorders - physiopathology</topic><topic>Child, Preschool</topic><topic>Cyclohexanols - adverse effects</topic><topic>Cyclohexanols - therapeutic use</topic><topic>Depression</topic><topic>Depressive Disorder - drug therapy</topic><topic>Depressive Disorder - physiopathology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Intelligence</topic><topic>Intelligence - drug effects</topic><topic>Intelligence - physiology</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental depression</topic><topic>Mood disorders</topic><topic>Neonatal Abstinence Syndrome - diagnosis</topic><topic>Neonatal Abstinence Syndrome - physiopathology</topic><topic>Neuropharmacology</topic><topic>Neuropsychology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pregnancy</topic><topic>Pregnancy Complications - drug therapy</topic><topic>Pregnancy Complications - physiopathology</topic><topic>Prenatal development</topic><topic>Prenatal exposure</topic><topic>Prenatal Exposure Delayed Effects</topic><topic>Prospective Studies</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Reference Values</topic><topic>Retrospective Studies</topic><topic>Serotonin Uptake Inhibitors - adverse effects</topic><topic>Serotonin Uptake Inhibitors - therapeutic use</topic><topic>Sex Factors</topic><topic>Venlafaxine Hydrochloride</topic><topic>Wechsler Scales</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nulman, Irena</creatorcontrib><creatorcontrib>Koren, Gideon</creatorcontrib><creatorcontrib>Rovet, Joanne</creatorcontrib><creatorcontrib>Barrera, Maru</creatorcontrib><creatorcontrib>Pulver, Ariel</creatorcontrib><creatorcontrib>Streiner, David</creatorcontrib><creatorcontrib>Feldman, Brian</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>British Nursing Index</collection><jtitle>The American journal of psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nulman, Irena</au><au>Koren, Gideon</au><au>Rovet, Joanne</au><au>Barrera, Maru</au><au>Pulver, Ariel</au><au>Streiner, David</au><au>Feldman, Brian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression</atitle><jtitle>The American journal of psychiatry</jtitle><addtitle>Am J Psychiatry</addtitle><date>2012-11-01</date><risdate>2012</risdate><volume>169</volume><issue>11</issue><spage>1165</spage><epage>1174</epage><pages>1165-1174</pages><issn>0002-953X</issn><eissn>1535-7228</eissn><coden>AJPSAO</coden><abstract>An examination of children of depressed mothers at age 3–6 found that IQs are lower in these children than in children of nondepressed mothers, and behavioral problems are somewhat more common. However, neither difference was related to prenatal antidepressant dose or duration. The child’s IQ is influenced by the mother’s IQ and child’s sex. Behavioral problems are associated with the severity of the mother’s depression not only during gestation but also during early childhood. ObjectiveEffects on child neurodevelopment of neurotransmitter reuptake inhibitors used as antidepressants during pregnancy have not been adequately studied. The authors compared the effects of prenatal exposure to venlafaxine (serotonin-norepinephrine reuptake inhibitor), selective serotonin reuptake inhibitors (SSRIs), and maternal depression.MethodA cohort derived from a prospectively collected database included four groups of children born to 1) depressed women who took venlafaxine during pregnancy (N=62), 2) depressed women who took SSRIs during pregnancy (N=62), 3) depressed women who were untreated during pregnancy (N=54), and 4) nondepressed, healthy women (N=62). The children’s intelligence and behavior outcomes were evaluated with standardized instruments at one time point between the ages of 3 years and 6 years, 11 months.ResultsThe children exposed to venlafaxine, SSRIs, and maternal depression during pregnancy had similar full-scale IQs (105, 105, and 108, respectively). The IQs of the venlafaxine and SSRI groups were significantly lower than that of the children of nondepressed mothers (112). The three groups exposed to maternal depression had consistently, but nonsignificantly, higher rates of most problematic behaviors than the children of nondepressed mothers. Severity of maternal depression in pregnancy and at testing predicted child behavior. Maternal IQ and child sex predicted child IQ. Antidepressant dose and duration during pregnancy did not predict any cognitive or behavioral outcome.ConclusionsFactors other than antidepressant exposure during pregnancy strongly predict children’s intellect and behavior. Depression during pregnancy is a significant risk factor for postpartum depression. Children of depressed mothers may be at risk of future psychopathology.</abstract><cop>Arlington, VA</cop><pub>American Psychiatric Association</pub><pmid>23128923</pmid><doi>10.1176/appi.ajp.2012.11111721</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-953X
ispartof The American journal of psychiatry, 2012-11, Vol.169 (11), p.1165-1174
issn 0002-953X
1535-7228
language eng
recordid cdi_proquest_miscellaneous_1466093672
source MEDLINE; American Psychiatric Publishing; EZB Electronic Journals Library
subjects Abnormalities, Drug-Induced - diagnosis
Abnormalities, Drug-Induced - physiopathology
Adult
Adult and adolescent clinical studies
Antidepressants
Antidepressive Agents, Second-Generation - adverse effects
Antidepressive Agents, Second-Generation - therapeutic use
Biological and medical sciences
Case-Control Studies
Child Behavior Disorders - chemically induced
Child Behavior Disorders - physiopathology
Child, Preschool
Cyclohexanols - adverse effects
Cyclohexanols - therapeutic use
Depression
Depressive Disorder - drug therapy
Depressive Disorder - physiopathology
Dose-Response Relationship, Drug
Female
Humans
Infant
Infant, Newborn
Intelligence
Intelligence - drug effects
Intelligence - physiology
Longitudinal Studies
Male
Medical sciences
Mental depression
Mood disorders
Neonatal Abstinence Syndrome - diagnosis
Neonatal Abstinence Syndrome - physiopathology
Neuropharmacology
Neuropsychology
Pharmacology. Drug treatments
Pregnancy
Pregnancy Complications - drug therapy
Pregnancy Complications - physiopathology
Prenatal development
Prenatal exposure
Prenatal Exposure Delayed Effects
Prospective Studies
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Reference Values
Retrospective Studies
Serotonin Uptake Inhibitors - adverse effects
Serotonin Uptake Inhibitors - therapeutic use
Sex Factors
Venlafaxine Hydrochloride
Wechsler Scales
title Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T21%3A35%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neurodevelopment%20of%20Children%20Following%20Prenatal%20Exposure%20to%20Venlafaxine,%20Selective%20Serotonin%20Reuptake%20Inhibitors,%20or%20Untreated%20Maternal%20Depression&rft.jtitle=The%20American%20journal%20of%20psychiatry&rft.au=Nulman,%20Irena&rft.date=2012-11-01&rft.volume=169&rft.issue=11&rft.spage=1165&rft.epage=1174&rft.pages=1165-1174&rft.issn=0002-953X&rft.eissn=1535-7228&rft.coden=AJPSAO&rft_id=info:doi/10.1176/appi.ajp.2012.11111721&rft_dat=%3Cproquest_cross%3E2914564481%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1316094608&rft_id=info:pmid/23128923&rfr_iscdi=true